Journal
ONCOLOGY REPORTS
Volume 30, Issue 3, Pages 1455-1462Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2013.2566
Keywords
erythropoietin; ovarian adenocarcinoma; A2780; angiogenesis; human umbilical vein endothelial cell
Categories
Funding
- Slovak Research and Development Agency [VVCE-0001-07, LPP-0062-09]
- Scientific Grant Agency of the Ministry of Education of the Slovak Republic [VEGA 1/0296/09, VEGA 1/0733/12]
- NEXO (Network of Excellence in Oncology) [ITMS 26220120024]
Ask authors/readers for more resources
Erythropoietin (Epo) is a key regulator of erythroid cell proliferation, differentiation and apoptosis. In the form of the recombinant protein, it is widely used to treat various types of anemias, including that associated with cancer and with the myelosuppressive effects of chemotherapy, particularly platinum-based regimens. Our previous studies confirmed the presence of Epo receptors (EpoRs) in ovarian adenocarcinoma cell lines and demonstrated that long-term Epo treatment of A2780 cells resulted in the development of a phenotype exhibiting both enhanced Epo signaling and increased paclitaxel resistance. In the present study, we carried out a series of experiments to analyze the pro-angiogenic potential of Epo-treated A2780 and SKOV-3 cells. Our studies revealed that conditioned media of Epo-treated A2780 cells had a stimulative effect on human umbilical vein endothelial cells (HUVECs). This effect was only seen when A2780 cells were incubated under hypoxic conditions. Furthermore, Epo increased the secretion of interleukin (IL)-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, GM-CSF and interferon-. by A2780 cells that grew in hypoxic conditions. In this regard, conditioned media of hypoxic and Epo-treated A2780 cells induced a significant phosphorylation of STAT-5 in HUVECs. Our results may have important implications for ovarian cancer patients receiving Epo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available